MedTrace Logo

Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders

NCT04485039 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2024-12-27

Study results available
· View outcomes & findings →

Summary

An open-label, drug-drug interaction study with TPOXX and phosphate binders.

Conditions

Interventions

DRUG

Tecovirimat

oral antiviral

DRUG

sevelamer carbonate oral tablet

phosphate binder

DRUG

sucroferric oxyhydroxide chewable tablet

phosphate binder

DRUG

calcium acetate oral tablet

phosphate binder

DRUG

Lanthanum Carbonate Chewable Tablet

phosphate binder

Sponsors & Collaborators

Principal Investigators

  • Dennis Hruby, PhD · SIGA Technologies Chief Scientific Officer

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-08
Primary Completion
2022-12-15
Completion
2023-04-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04485039 on ClinicalTrials.gov